Cyclopharm (ASX:CYC) said the first 15 of 665 patients were imaged in a Pronospect clinical trial across 13 French nuclear medicine centers, according to a Tuesday filing with the Australian bourse.

The trial is examining the potential of nuclear medicine imaging using Technegas to enable improved detection of residual pulmonary vascular obstruction as a predictor of venous thromboembolism recurrence, the filing said.

The trial involves patients diagnosed with pulmonary embolism who have completed three to six months of anticoagulation treatment, according to the filing.

Venous thromboembolism is a blood clot that blocks blood flow in the veins, while pulmonary embolism is a blood clot that breaks off and travels to the lungs.

Cyclopharm shares rose nearly 1% in midday trade Tuesday.

Price (AUD): $1.66, Change: $+0.01, Percent Change: +0.61%